Skydance's David Ellison tells CNBC combined company is 'positioned to win in every single vertical'
Skydance includes two film studios, the CBS broadcast network, a sprawling pay TV portfolio and streaming services Paramount+ and HBO Max.
On October 5, 2026, CEO David Kirn of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) divested a portion of their company's common stock, selling shares amounting to $753,937 in total. The sales were executed according to a pre-set 10b5-1 trading plan that Kirn established on January 9, 2026. The shares were divided into two parcels: 58,061 shares were sold at prices fluctuating between $12.61 and $13.60 per share, averaging a sale price of $12.9215.
Separately, 272 shares were traded at prices between $13.61 and $13.63 per share, with an average sale price of $13.6104. As of the current market, the stock trades at $12.59, marking a decline of approximately 9% over the preceding week. Despite this recent dip, the stock price has increased by 68% year-to-date. According to InvestingPro, FDMT appears to be undervalued at these levels, positioning the stock as an opportunity on their list of undervalued stocks.
Subscribers of InvestingPro gain access to over 10 exclusive tips for FDMT, in addition to Fair Value estimates and comprehensive financial health scores. Post these transactions, David Kirn personally owns 709,153 shares of 4D Molecular Therapeutics common stock. In recent news, 4D Molecular Therapeutics has been subject to various analyst reviews and updates.
BofA Securities has raised its price target for the company from $29 to $33, maintaining a Buy rating, influenced by the positive outcomes of the SPECTRA trial and the commencement of the Phase 3 4SIGHT trial for diabetic macular edema. Cantor Fitzgerald has upgraded 4D Molecular’s stock to Overweight from Neutral, expressing optimism about the company’s gene therapy advancements, particularly in wet age-related macular degeneration and diabetic macular edema.
H.C. Wainwright and B.Riley have also reiterated Buy ratings for the company, with price targets of $36 and $37 respectively, emphasizing the de-risked status of the company’s Phase 3 studies. These analyst sentiments suggest a generally optimistic outlook for 4D Molecular Therapeutics’ ongoing trials and future prospects.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
